Hashemi-Sadraei N, et al. - The clinical characteristics and outcomes of patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) who achieved pathologic complete response (pCR) after neoadjuvant therapy were characterized. Researchers studied the clinical database for patients with pancreatic ductal adenocarcinoma from a single institution. In a small number of patients with borderline resectable/locally advanced pancreatic adenocarcinoma, multimodality neoadjuvant therapy may result in pCR. However, most of the time, pCR is not seen in response to neoadjuvant therapy, and most patients appear to relapse locally or systemically.